Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Chronic obstructive pulmonary disease (COPD)
- Definition of COPD
- Is COPD genetically determined?
- Phenotypes of COPD
- Current risk prediction for COPD
- Smoking and alpha 1 antitrypsin deficiency
- Relation between FEV1 and smoking
- Nottingham smokers
- Conclusions so far
- Value of genetics
- Approaches to COPD genetics
- Genome wide association studies
- Genomic variation of likely relevance to disease
- Structure of GWAS on lung function
- Meta-analysis of GWAS on lung function
- Lung function GWAS (SpiroMeta & CHARGE)
- SpiroMeta & CHARGE GWAS: results
- Associations with COPD
- Key genes associated with lung function & COPD
- Genetic architecture of lung function
- Key question
- Strategy for functional studies
- Expression profiling
- Overview of the RAGE receptor
- SNPs in RAGE are associated with lung function
- Expression of the RAGE receptor
- Summary on RAGE
- Overall summary
- Acknowledgements
Topics Covered
- COPD-important world-wide cause of morbidity and mortality
- Clear evidence of a genetic contribution to disease risk
- Genome wide association studies have identified genes predicting lung function
- Role of these genes in COPD pathophysiology
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hall, I. (2014, March 5). Genetics of COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 12, 2024, from https://doi.org/10.69645/OMKY4966.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Ian Hall has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cell Biology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Professor Ian Hall.
I'm the dean at the University
of Nottingham Medical School.
And today I'm going to talk
to you about the genetics
of chronic obstructive
pulmonary disease, or COPD.
0:14
COPD accounts for over 900,000
patients within the UK.
30,000 people die of this
disease every year in the UK.
And the health care costs to
the National Health Service
are in the order of half
a billion pounds per year.
In the USA, in 2006, 12
million adults had COPD.
And over 670,000 hospital admissions
were recorded due to COPD.
Over 120,000 people will die of
COPD in any given year in the USA.
Globally, it is the fourth
leading cause of death
and is set to rise
to the third leading
cause of death in
the next few years.
This is partly because of the
increased life expectancy of people
in the developing world
and the onset of COPD
in people who are in
their later years.
1:08
COPD is defined as the presence of
irreversible airflow obstruction
with a ratio between the forced
expiratory volume in one second
and the forced vital
capacity of less than 70%,
and a reduction in the FEV1 itself.
Criteria based upon the
severity of airflow obstruction
have been used for many years
to assess the severity of COPD.
These are known as
the GOLD criteria.
Although these have recently
been revised to take into
account the exacerbation
frequency in addition
to the severity of
airflow obstruction.
Histopathological changes present
in the lungs of patients with COPD
tend to show either small
airway destruction or emphysema,
or narrowing of the
small or medium-sized
airways due to chronic bronchitis.